A #WCLC24 session unveiled promising preliminary findings for a novel targeted TKI to treat HER2-mutated NSCLC. Discover more insights in #ILCN: https://bit.ly/4gSi5fb #LCSM
International Association for the Study of Lung Cancer
Non-profit Organizations
Denver, Colorado 10,230 followers
Conquering thoracic cancers worldwide.
About us
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer. Founded in 1974, the association’s membership includes nearly 9,000 lung cancer specialists in over 100 countries. The IASLC's seeks to conquer thoracic cancers worldwide through educating scientists, medical professionals and the public on all aspects of lung cancer and other thoracic malignancies. The association publishes the Journal of Thoracic Oncology, a primary resource on the detection, prevention, diagnosis and treatment of lung cancer. Finally, each year the IASLC also hosts the IASLC World Conference on Lung Cancer (WCLC), the world's largest meeting dedicated solely to the study and science of thoracic cancers. The WCLC regularly draws 7,000 thoracic cancer specialists from over 100 countries.
- Website
-
http://www.iaslc.org/
External link for International Association for the Study of Lung Cancer
- Industry
- Non-profit Organizations
- Company size
- 11-50 employees
- Headquarters
- Denver, Colorado
- Type
- Nonprofit
- Founded
- 1974
- Specialties
- Journal of Thoracic Oncology (JTO), Thoracic Oncology, Lung Cancer, Cancer Research, Medical Education, and Science
Locations
-
Primary
1775 N Sherman St
Denver, Colorado 80203, US
Employees at International Association for the Study of Lung Cancer
Updates
-
Press Release: The #IASLC named four thoracic oncology experts to co-chair the 2026 World Conference on Lung Cancer (#WCLC26), to be held September 12 -15, 2026 in Seoul, South Korea: - Myung-Ju Ahn, MD, PhD, from Sungkyunkwan University School of Medicine, Seoul, South Korea. - Wentao Fang, MD, from Jiaotong University School of Medicine in Shanghai, China. - Jiraporn Setakornnukul. MD, PhD, from Siriraj Hospital, Mahidol University in Bangkok, Thailand. - Yasushi Yatabe MD, PhD from National Cancer Center of Japan, Tokyo, Japan. Learn More: https://lnkd.in/gB4tKZVQ #LCSM
-
Register for #HTTR24! Let's dive deep into the mechanisms, biomarkers & models that drive our understanding/treatment of drug tolerance & resistance in #NSCLC. You will collaborate w/leading experts & contribute to the future of #lungcancer therapy. Register Now: https://bit.ly/HTTR24-Reg #LCSM
-
#WCLC24 Recap: Dr. Hisao Asamura reviewed the criteria changes in the new 9th edition of the TNM classification recommendations. Learn more in #ILCN: https://bit.ly/4dFJBtv #LCSM
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging - ILCN.org (ILCN/WCLC)
https://www.ilcn.org
-
On Monday 10/21/24 @ 6AM MDT, the #IASLC's Education Committee will present a 1-hour live session focused on providing a concise & comprehensive update on the most impactful studies related to thoracic tumors presented during #ESMO24. Register Now: https://bit.ly/ESMO24Web #LCSM
-
On Monday 10/21/24 @ 6AM MDT, the #IASLC's Education Committee will present a 1-hour live session focused on providing a concise & comprehensive update on the most impactful studies related to thoracic tumors presented during #ESMO24. Register Now: https://bit.ly/ESMO24Web #LCSM
-
Abstract submission is now open for #ELCC25, organized by #IASLC & #ESMO. The deadline to submit is Tuesday, January 14, 2025 @ 21:00 CET, and Tuesday, February 18, 2025 @ 21:00 CET for Late-Breaking Abstracts (LBA). Learn More & Submit Here: https://bit.ly/ESMO25-Abs #LCSM
-
Anti Drug Conjugates represent a new way of treating thoracic, breast & gastrointestinal cancers. Despite recent successes, many ADCs failed during clinical development due to excessive toxicities & unfavorable risk-benefit profiles. In this episode of #LungCancerConsidered, host Dr. Narjust Florez discusses ADCs, and how clinicians can manage some of these toxicities. W/guests Dr. Benjamin Levy, from the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, and Dr. Paolo Tarantino, from the Dana-Farber Cancer Institute. Listen Now: https://bit.ly/ADCTox #LCSM
-
ICYMI: New drug approvals in Europe and China. Plus, the US FDA grants priority review and breakthrough therapy designation to durvalumab. Read the latest in #ILCN: https://bit.ly/3TLkyhj #LCSM
In Brief for September 25, 2024 - ILCN.org (ILCN/WCLC)
https://www.ilcn.org
-
The #IASLC's Education Committee will present a 1-hour live session focused on providing a concise & comprehensive update on the most impactful studies related to thoracic tumors presented during the #ESMO24 Meeting, Join Us! Registration: https://bit.ly/ESMO24Web #LCSM